Stockreport

C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact [Seeking Alpha]

C4 Therapeutics, Inc.  (CCCC) 
NASDAQ:AMEX Investor Relations: ir.chinacache.com
PDF CCCC's lead asset, cemsidomide, advanced into a Phase 2 registrational trial for relapsed/refractory multiple myeloma, targeting a large, growing TAM. Cash position s [Read more]